R1 RCM has launched a $3.1 billion term loan B along with a $200 million delayed-draw term loan backing the take-private buyout of the company by TowerBrook Capital Partners and Clayton, Dubilier & Rice (CD&R), according to sources. Commitments are due by noon ET Friday, Oct. 25.
Price talk for the seven-year covenant-lite TLB is S+350-375, with a 0% floor and an OID of 99.5. There is a 25 bps margin step-down at 0.5x inside closing first-lien leverage. Lenders are offered six months of 101 soft call protection. The DDTL will be available for 24 months. There is no ticking fee on the DDTL for the first 60 days, and then the fee is 50% of margin for days 61-90, stepping to 100% of the margin thereafter.
At talk, the yield to maturity works out to around 8.52%-8.78%.
Deutsche Bank is leading the deal and joint bookrunners are RBC Capital Markets, TD Securities, UBS, Wells Fargo, BNP Paribas, Santander, Mizuho, Natixis, SMBC, Citizens, Apollo Global Funding, Ares and Golub Capital. Deutsche Bank is administrative agent.
S&P Global Ratings today assigned corporate and facility ratings of B-, with a positive outlook, and there is a recovery rating of 3 on the loan. Raven Acquisition Holdings LLC is the borrower.
The company in August announced that it was being acquired by the private equity firms in a deal with an enterprise value of $8.9 billion. Under the terms of the agreement, TowerBrook and CD&R will acquire all the outstanding common stock that TowerBrook does not already own for $14.30 per share. TowerBrook currently holds roughly 36% of R1 RCM’s outstanding shares. In addition to the term loan facility, the deal will be financed with $1 billion of secured notes. The financing commitment also provides for a $687.5 million, five-year senior secured revolver. Required regulatory approvals were obtained and closing of the transaction is expected by year-end, subject to shareholder approval.
R1 RCM’s existing debt includes a covenant-lite TLB due June 2029 (S+300, 0.5% floor) that totaled $1.066 billion as of June 30. The company last tapped the market in December when it added on to the TLB to fund its acquisition of Acclara. At quarter-end there was also $1.147 billion outstanding under a term loan A facility split between an initial tranche due July 2026 and an incremental tranche due June 2027. In addition, the company has a $600 million revolver due July 2026. Pricing on the pro rata facilities is on a grid tied to total net leverage and ranges between S+125-250, with a 0% floor. The TLA and revolver are subject to total net leverage and interest coverage covenants. Bank of America is administrative agent.
R1 RCM is a Chicago-based provider of technology-enabled revenue cycle management services to healthcare providers.
Featured image: Utah778/Getty Images
Learn about our editorial standards.